282 related articles for article (PubMed ID: 35716323)
21. Indoleamine 2,3-dioxygenase, by degrading L-tryptophan, enhances carnitine palmitoyltransferase I activity and fatty acid oxidation, and exerts fatty acid-dependent effects in human alloreactive CD4+ T-cells.
Eleftheriadis T; Pissas G; Sounidaki M; Tsogka K; Antoniadis N; Antoniadi G; Liakopoulos V; Stefanidis I
Int J Mol Med; 2016 Nov; 38(5):1605-1613. PubMed ID: 27667153
[TBL] [Abstract][Full Text] [Related]
22. Targeting the IDO1 pathway in cancer: from bench to bedside.
Liu M; Wang X; Wang L; Ma X; Gong Z; Zhang S; Li Y
J Hematol Oncol; 2018 Aug; 11(1):100. PubMed ID: 30068361
[TBL] [Abstract][Full Text] [Related]
23. Tryptophan Catabolism and Cancer Immunotherapy Targeting IDO Mediated Immune Suppression.
Amobi A; Qian F; Lugade AA; Odunsi K
Adv Exp Med Biol; 2017; 1036():129-144. PubMed ID: 29275469
[TBL] [Abstract][Full Text] [Related]
24. Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells.
Curti A; Trabanelli S; Onofri C; Aluigi M; Salvestrini V; Ocadlikova D; Evangelisti C; Rutella S; De Cristofaro R; Ottaviani E; Baccarani M; Lemoli RM
Haematologica; 2010 Dec; 95(12):2022-30. PubMed ID: 20801903
[TBL] [Abstract][Full Text] [Related]
25. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.
Wainwright DA; Chang AL; Dey M; Balyasnikova IV; Kim CK; Tobias A; Cheng Y; Kim JW; Qiao J; Zhang L; Han Y; Lesniak MS
Clin Cancer Res; 2014 Oct; 20(20):5290-301. PubMed ID: 24691018
[TBL] [Abstract][Full Text] [Related]
26. 4,5-Disubstituted 1,2,3-triazoles: Effective Inhibition of Indoleamine 2,3-Dioxygenase 1 Enzyme Regulates T cell Activity and Mitigates Tumor Growth.
Panda S; Pradhan N; Chatterjee S; Morla S; Saha A; Roy A; Kumar S; Bhattacharyya A; Manna D
Sci Rep; 2019 Dec; 9(1):18455. PubMed ID: 31804586
[TBL] [Abstract][Full Text] [Related]
27. H
Yang D; Li T; Li Y; Zhang S; Li W; Liang H; Xing Z; Du L; He J; Kuang C; Yang Q
J Exp Clin Cancer Res; 2019 Feb; 38(1):88. PubMed ID: 30777103
[TBL] [Abstract][Full Text] [Related]
28. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival.
Wainwright DA; Balyasnikova IV; Chang AL; Ahmed AU; Moon KS; Auffinger B; Tobias AL; Han Y; Lesniak MS
Clin Cancer Res; 2012 Nov; 18(22):6110-21. PubMed ID: 22932670
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites.
Terness P; Bauer TM; Röse L; Dufter C; Watzlik A; Simon H; Opelz G
J Exp Med; 2002 Aug; 196(4):447-57. PubMed ID: 12186837
[TBL] [Abstract][Full Text] [Related]
30. Remarkable role of indoleamine 2,3-dioxygenase and tryptophan metabolites in infectious diseases: potential role in macrophage-mediated inflammatory diseases.
Murakami Y; Hoshi M; Imamura Y; Arioka Y; Yamamoto Y; Saito K
Mediators Inflamm; 2013; 2013():391984. PubMed ID: 23476103
[TBL] [Abstract][Full Text] [Related]
31. Indoleamine 2,3-dioxygenase: is it an immune suppressor?
Soliman H; Mediavilla-Varela M; Antonia S
Cancer J; 2010; 16(4):354-9. PubMed ID: 20693847
[TBL] [Abstract][Full Text] [Related]
32. Salinomycin promotes T-cell proliferation by inhibiting the expression and enzymatic activity of immunosuppressive indoleamine-2,3-dioxygenase in human breast cancer cells.
Ebokaiwe AP; Njoya EM; Sheng Y; Zhang Z; Li S; Zhou Z; Qiang Z; Peng T; Hussein AA; Zhang G; Lu X; Li L; Wang F
Toxicol Appl Pharmacol; 2020 Oct; 404():115203. PubMed ID: 32822738
[TBL] [Abstract][Full Text] [Related]
33. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond.
Muller AJ; Manfredi MG; Zakharia Y; Prendergast GC
Semin Immunopathol; 2019 Jan; 41(1):41-48. PubMed ID: 30203227
[TBL] [Abstract][Full Text] [Related]
34. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion.
Platten M; Wick W; Van den Eynde BJ
Cancer Res; 2012 Nov; 72(21):5435-40. PubMed ID: 23090118
[TBL] [Abstract][Full Text] [Related]
35. Indoleamine 2,3-Dioxygenase Activity-Induced Acceleration of Tumor Growth, and Protein Kinases-Related Novel Therapeutics Regimens.
Engin AB; Engin A
Adv Exp Med Biol; 2021; 1275():339-356. PubMed ID: 33539022
[TBL] [Abstract][Full Text] [Related]
36. The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells.
Opitz CA; Litzenburger UM; Opitz U; Sahm F; Ochs K; Lutz C; Wick W; Platten M
PLoS One; 2011; 6(5):e19823. PubMed ID: 21625531
[TBL] [Abstract][Full Text] [Related]
37. Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor.
Balog A; Lin TA; Maley D; Gullo-Brown J; Kandoussi EH; Zeng J; Hunt JT
Mol Cancer Ther; 2021 Mar; 20(3):467-476. PubMed ID: 33298590
[TBL] [Abstract][Full Text] [Related]
38. Up-regulated expression of indoleamine 2,3-dioxygenase 1 in non-Hodgkin lymphoma correlates with increased regulatory T-cell infiltration.
Liu XQ; Lu K; Feng LL; Ding M; Gao JM; Ge XL; Wang X
Leuk Lymphoma; 2014 Feb; 55(2):405-14. PubMed ID: 23682557
[TBL] [Abstract][Full Text] [Related]
39. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
[TBL] [Abstract][Full Text] [Related]
40. The immunotherapeutic role of indoleamine 2,3-dioxygenase in head and neck squamous cell carcinoma: A systematic review.
Lin DJ; Ng JCK; Huang L; Robinson M; O'Hara J; Wilson JA; Mellor AL
Clin Otolaryngol; 2021 Sep; 46(5):919-934. PubMed ID: 34053179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]